It is a 39-amino acid, acylated polypeptide belonging to the group of dual receptor agonists GIP and GLP-1
With increasing clinical evidence, GLP-1RAs are set to become essential in treating complex and chronic diseases, offering significant health benefits and addressing unmet medical needs, thus enhancing patient quality of life and solidifying their role in future medical advancements
14-16,19,33 Medications that we commonly discuss with patients in our clinic, as considerations for use, are listed in Table 2
Of these, 35 were randomized controlled trials, although only 28 of these trials included a control group during the intervention and follow-up period
- Sueo: Mejora la calidad del sueo
Rashmi D, Zanan R, John S, Khandagale K, Nadaf A